PBX1: A Potential Drug Target for Pre-B-Cell Leukemia (G5087)

Target Name: PBX1

NCBI ID: G5087

PBX1

PBX1: A Potential Drug Target for Pre-B-Cell Leukemia

PBX1 (pre-B-cell leukemia homeobox 1) is a protein that is expressed in a variety of tissues throughout the body, including the bone marrow, where it is a component of the development and maintenance of normal blood cells. It is also known as PLZF1, and it has been identified as a potential drug target for the treatment of pre-B-cell leukemia.

Pre-B-cell leukemia is a type of cancer that affects the bone marrow, where the blood cells are produced. It is characterized by the production of abnormal white blood cells called leukemia cells, which do not function properly and can accumulate in the bone marrow and bloodstream. Pre-B-cell leukemia is a serious and potentially life-threatening condition that is often treated with chemotherapy, but the treatment can have a number of negative side effects.

One of the challenges in the treatment of pre-B-cell leukemia is the development of resistance to the chemotherapy drugs that are used to treat the disease. This is because pre-B-cell leukemia cells are very resilient and can evolve over time to become less responsive to the chemotherapy drugs. The development of resistance to chemotherapy is a major factor in the treatment failure rate for this type of cancer.

PBX1 is a protein that has been shown to be involved in the development and maintenance of normal blood cells. It is also involved in the regulation of cell growth and in the development of cancer. In addition, PBX1 has been shown to be involved in the development of pre-B-cell leukemia.

Research has shown that PBX1 is expressed in the bone marrow and is involved in the development and maintenance of normal B cells. It is also shown to be involved in the regulation of cell growth and in the development of cancer. Studies have also shown that PBX1 is a potential drug target for the treatment of pre-B-cell leukemia.

One of the potential benefits of targeting PBX1 with drugs is that it can inhibit the development of pre-B-cell leukemia cells and potentially lead to the treatment of the disease. Additionally, targeting PBX1 with drugs may also have the potential to reduce the development of resistance to the chemotherapy drugs that are used to treat the disease.

In conclusion, PBX1 is a protein that has been identified as a potential drug target for the treatment of pre-B-cell leukemia. Further research is needed to understand the role of PBX1 in the development and maintenance of normal blood cells and in the development of cancer. Additionally, research is needed to determine the effectiveness of targeting PBX1 with drugs as a treatment for pre-B-cell leukemia.

Protein Name: PBX Homeobox 1

Functions: Transcription factor which binds the DNA sequence 5'-TGATTGAT-3' as part of a heterodimer with HOX proteins such as HOXA1, HOXA5, HOXB7 and HOXB8 (PubMed:9191052). Binds to the DNA sequence 5'-TGATTGAC-3' in complex with a nuclear factor which is not a class I HOX protein (PubMed:9191052). Has also been shown to bind the DNA sequence 5'-ATCAATCAA-3' cooperatively with HOXA5, HOXB7, HOXB8, HOXC8 and HOXD4 (PubMed:8327485, PubMed:7791786). Acts as a transcriptional activator of PF4 in complex with MEIS1 (PubMed:12609849). Also activates transcription of SOX3 in complex with MEIS1 by binding to the 5'-TGATTGAC-3' consensus sequence (By similarity). In natural killer cells, binds to the NFIL3 promoter and acts as a transcriptional activator of NFIL3, promoting natural killer cell development (By similarity). Plays a role in the cAMP-dependent regulation of CYP17A1 gene expression via its cAMP-regulatory sequence (CRS1) (By similarity). Probably in complex with MEIS2, involved in transcriptional regulation by KLF4 (PubMed:21746878). Acts as a transcriptional activator of NKX2-5 and a transcriptional repressor of CDKN2B (By similarity). Together with NKX2-5, required for spleen development through a mechanism that involves CDKN2B repression (By similarity)

The "PBX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PBX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets